Mates Sharon — SEC Form 4 filings
SEC reporting owner CIK 1585699. 20 Form 4 filings on record with FilingPulse; latest filed 2026-05-04.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2024-01-18 to 2026-05-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 38 legs across 8 filings — 698,809 shares, $50,531,010 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 71.
- Largest priced transaction: sale of 65,979 shares @ $67.25 ($4,437,088) in Intra-Cellular Therapies, Inc., filed 2024-01-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Intra-Cellular Therapies, Inc. (ITCI) | Chairman and CEO, Director | 16 | — | 38 legs · 698,809 sh · $50,531,010 | 67 |
| Benitec Biopharma Inc. (BNTC) | Director | 3 | — | — | 3 |
| Seaport Therapeutics, Inc. (SPTX) | Director | 1 | — | — | 1 |
Form 4 filings — Mates Sharon
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) | Grant/award (A): 49,033 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Benitec Biopharma Inc. (BNTC) | Grant/award (A): 31,500 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Benitec Biopharma Inc. (BNTC) | Grant/award (A): 3,500 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | Benitec Biopharma Inc. (BNTC) | Grant/award (A): 28,517 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Disposition to issuer (D): 945,235 @ $132 · Disposition to issuer (D): 190,000 @ $132 · Disposition to issuer (D): 86,003 (derivative) · Disposition to issuer (D): 135,399 (derivative) · Disposition to issuer (D): 138,473 (derivative) · Disposition to issuer (D): 66,886 (derivative) · +9 more | EDGAR |
| 2025-03-31 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Gift (G): 190,000 @ $0 · Gift (G): 190,000 @ $0 | EDGAR |
| 2025-03-10 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 40,712 · Tax withholding (F): 19,848 @ $131.19 · Option exercise (M): 20,566 · Tax withholding (F): 10,129 @ $131.24 · Option exercise (M): 40,712 (derivative) @ $0 · Option exercise (M): 20,566 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 34,969 · Tax withholding (F): 16,978 @ $128.20 · Option exercise (M): 34,969 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 30,847 @ $0 · Tax withholding (F): 15,233 @ $127 · Grant/award (A): 121,212 (derivative) @ $0 | EDGAR |
| 2024-12-06 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 51,000 @ $12.73 · Sale (S): 27,667 @ $85.62 · Sale (S): 23,333 @ $86.00 · Option exercise (M): 51,697 @ $12.73 · Sale (S): 50,163 @ $84.06 · Sale (S): 1,534 @ $84.69 · +2 more | EDGAR |
| 2024-08-30 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 35,604 @ $12.73 · Sale (S): 29,832 @ $72.44 · Sale (S): 5,772 @ $73.25 · Option exercise (M): 34,396 @ $12.73 · Sale (S): 28,203 @ $72.73 · Sale (S): 6,193 @ $73.32 · +2 more | EDGAR |
| 2024-08-28 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 22,713 @ $17.57 · Sale (S): 22,713 @ $74.59 · Option exercise (M): 40,513 @ $17.57 · Sale (S): 23,657 @ $73.33 · Sale (S): 16,856 @ $73.93 · Option exercise (M): 32,699 @ $17.57 · +5 more | EDGAR |
| 2024-08-23 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 53,013 @ $17.57 · Sale (S): 44,134 @ $75.40 · Sale (S): 4,297 @ $76.20 · Sale (S): 2,682 @ $77.21 · Sale (S): 1,900 @ $77.98 · Option exercise (M): 39,380 @ $17.57 · +7 more | EDGAR |
| 2024-04-25 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 8,638 @ $16.86 · Option exercise (M): 11,382 @ $17.57 · Option exercise (M): 8,638 (derivative) @ $0 · Option exercise (M): 11,382 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Sale (S): 31,958 @ $66.38 · Sale (S): 8,754 @ $66.93 · Option exercise (M): 20,565 · Sale (S): 14,541 @ $64.80 · Sale (S): 4,128 @ $65.90 · Sale (S): 1,590 @ $66.81 · +2 more | EDGAR |
| 2024-03-08 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 40,712 · Option exercise (M): 40,712 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 104,909 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 22,590 · Sale (S): 600 @ $68.39 · Sale (S): 9,528 @ $69.45 · Sale (S): 12,462 @ $70.11 · Option exercise (M): 22,590 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 33,885 @ $0 · Sale (S): 16,435 @ $66.70 · Sale (S): 17,450 @ $67.42 | EDGAR |
| 2024-01-18 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 75,361 @ $16.86 · Sale (S): 3,500 @ $66.38 · Sale (S): 65,979 @ $67.25 · Sale (S): 5,882 @ $67.76 · Option exercise (M): 48,084 @ $16.86 · Sale (S): 30,633 @ $66 · +7 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1585699 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →